Completed trials from CCIT-DK This is a list of completed trials from CCIT-DK with links to descriptions on www.clinicaltrials.gov Sideindhold Adoptive Cell Therapy across Cancer DiagnosesArginase-1 Peptide Vaccine in Patients with Metastatic Solid TumorsA Study of IO103 in Montanide Adjuvant for Basal Cell CarcinomaBcl-XL_42-CAF09b Vaccination for Patients with Prostate CancerCALR Exon 9 Mutant Peptide Vaccine to Patients with CALR-mutant Myeloproliferative NeoplasmsCombination Therapy Nivolumab and PD-L1/IDO Peptide for Metastatic MelanomaComparing TIL to Standard Ipilimumab Dendritic Cell Based Therapy of Metastic Breast CancerDendritic Cell Based Therapy of Malignant MelanomaDendritic Cell Based Therapy of Renal Cell CarcinomaDendritic Cell Vaccination and Docetaxel for Patients With Prostate CancerDual Vaccine Trial in Myeloproliferative NeoplasmsIDO Peptide Vaccination for Stage III-IV Non Small-cell Lung Cancer PatientsExercise-induced Effects on Immune Parameters in Healthy Participants ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic MelanomaPeginterferon and TIL Therapy for Metastatic Melanoma Peptide Vaccine and Temozolomide for Metastatic Melanoma PatientsPersonalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac) (NeoPepVac) T-cell Based Immunotherapy for of Melanoma T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian CancerTIL Therapy in Combination with Checkpoint Inhibitors for Metastatic Ovarian CancerTIL Therapy for Metastatic Ovarian CancerTIL Therapy for Metastatic Renal Cell CarcinomaTNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma Transfected Dendritic Cell Based Therapy for Patiens with Breast Cancer or Malignant MelanomaTreatment Efficacy of Corticosteroids, Mycophenolate Mofetil and Tacrolimus in Patients With Immune Related Vaccination with Peptides in Combination with either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant MelanomaVemurafenib and TIL for Metastatic Melanoma Last updated: 8. July 2026 Redaktør Mette Wassard Yde Please give your consent in order to send your message. Please enter a valid email address. Write your message: Write your email (Must be filled out): If you wish to attach one or more files you will need to login first. Create account or log in I hereby give my consent to the Capital Region of Denmark to process the information in my enquiry for professional purposes only. Read the terms for your consent No e-mail has been registred for this user/group